GILD vs. BMY

Last updated Jun 4, 2026

GILD (Gilead Sciences, Inc.) and BMY (Bristol-Myers Squibb Company) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, GILD returned 7.86%/yr vs 0.60%/yr for BMY. At a 0.29 correlation, their price movements are largely independent.

Performance

GILD vs. BMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, GILD achieves a 5.69% return, which is significantly higher than BMY's 3.70% return. Over the past 10 years, GILD has outperformed BMY with an annualized return of 7.86%, while BMY has yielded a comparatively lower 0.60% annualized return.

GILD

• 1D: 1.11%
• 1M: -2.79%
• YTD: 5.69%
• 6M: 4.46%
• 1Y: 21.12%
• 3Y*: 22.39%
• 5Y*: 18.17%
• 10Y*: 7.86%

BMY

• 1D: 0.48%
• 1M: -4.64%
• YTD: 3.70%
• 6M: 9.77%
• 1Y: 19.47%
• 3Y*: -1.44%
• 5Y*: 0.60%
• 10Y*: 0.60%

*Multi-year figures are annualized to reflect compound growth (CAGR)

GILD vs. BMY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
GILD Gilead Sciences, Inc.	5.69%	36.59%	18.68%	-1.99%	23.63%	29.95%	-6.70%	7.88%	-9.92%	2.96%
BMY Bristol-Myers Squibb Company	3.70%	0.11%	15.81%	-26.14%	18.98%	2.88%	0.41%	27.74%	-12.90%	7.71%

Correlation

The correlation between GILD and BMY is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.33
Correlation (3Y) Calculated over the trailing 3-year period	0.41
Correlation (5Y) Calculated over the trailing 5-year period	0.43
Correlation (10Y) Calculated over the trailing 10-year period	0.40
Correlation (All Time) Calculated using the full available price history since Jan 23, 1992	0.29

The correlation between GILD and BMY shifts across timeframes, from 0.29 (all time) to 0.43 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap GILD : $161.75B BMY : $111.82B
EPS GILD : $7.35 BMY : $3.57
PE Ratio GILD : 17.55 BMY : 15.35
PEG Ratio GILD : 0.04 BMY : 0.88
PS Ratio GILD : 5.44 BMY : 2.30
PB Ratio GILD : 6.88 BMY : 5.57
Total Revenue (TTM) GILD : $29.74B BMY : $48.48B
Gross Profit (TTM) GILD : $18.74B BMY : $33.33B
EBITDA (TTM) GILD : $12.88B BMY : $13.34B

Return for Risk

GILD vs. BMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GILD

GILD Risk / Return Rank: 63
GILD Sharpe Ratio Rank: 66
GILD Sortino Ratio Rank: 61
GILD Omega Ratio Rank: 57
GILD Calmar Ratio Rank: 64
GILD Martin Ratio Rank: 66

BMY

BMY Risk / Return Rank: 63
BMY Sharpe Ratio Rank: 64
BMY Sortino Ratio Rank: 59
BMY Omega Ratio Rank: 56
BMY Calmar Ratio Rank: 67
BMY Martin Ratio Rank: 67

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GILD vs. BMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GILD	BMY	Difference
Sharpe ratio Return per unit of total volatility	0.81	0.74	+0.07
Sortino ratio Return per unit of downside risk	1.35	1.25	+0.10
Omega ratio Gain probability vs. loss probability	1.15	1.15	+0.01
Calmar ratio Return relative to maximum drawdown	1.20	1.43	-0.23
Martin ratio Return relative to average drawdown	3.03	3.16	-0.13
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GILD vs. BMY - Sharpe Ratio Comparison

The current GILD Sharpe Ratio is 0.81, which is comparable to the BMY Sharpe Ratio of 0.74. The chart below compares the historical Sharpe Ratios of GILD and BMY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	GILD	BMY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.81	0.74	+0.07
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.76	0.03	+0.74
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.31	0.02	+0.29
Sharpe Ratio (All Time) Calculated using the full available price history	0.39	0.34	+0.04

Drawdowns

GILD vs. BMY - Drawdown Comparison

The maximum GILD drawdown since its inception was -70.83%, roughly equal to the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for GILD and BMY.

Drawdown Indicators

	GILD	BMY	Difference
Max Drawdown Largest peak-to-trough decline	-70.83%	-72.03%	+1.20%
Max Drawdown (1Y) Largest decline over 1 year	-17.65%	-13.68%	-3.97%
Max Drawdown (3Y) Largest decline over 3 years	-26.59%	-36.85%	+10.26%
Max Drawdown (5Y) Largest decline over 5 years	-26.59%	-47.67%	+21.08%
Max Drawdown (10Y) Largest decline over 10 years	-30.47%	-47.67%	+17.20%
Current Drawdown Current decline from peak	-16.74%	-21.26%	+4.52%
Average Drawdown Average peak-to-trough decline	-22.16%	-22.38%	+0.22%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.98%	6.17%	+0.81%

Volatility

GILD vs. BMY - Volatility Comparison

Gilead Sciences, Inc. (GILD) has a higher volatility of 7.30% compared to Bristol-Myers Squibb Company (BMY) at 6.06%. This indicates that GILD's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GILD	BMY	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.30%	6.06%	+1.24%
Volatility (6M) Calculated over the trailing 6-month period	18.55%	18.48%	+0.07%
Volatility (1Y) Calculated over the trailing 1-year period	26.32%	26.64%	-0.32%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	24.04%	23.98%	+0.06%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.49%	25.24%	+0.25%

Dividends

GILD vs. BMY - Dividend Comparison

GILD's dividend yield for the trailing twelve months is around 2.47%, less than BMY's 4.57% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BMY Bristol-Myers Squibb Company	4.57%	4.60%	4.24%	4.44%	3.00%	2.36%	3.69%	2.55%	3.08%	2.55%	1.95%	2.17%
GILD Gilead Sciences, Inc.	2.47%	2.57%	3.33%	3.70%	3.40%	3.91%	4.67%	3.88%	3.65%	2.90%	2.57%	1.27%

Financials

GILD vs. BMY - Profitability Comparison

The chart below illustrates the profitability comparison between Gilead Sciences, Inc. and Bristol-Myers Squibb Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

GILD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Gilead Sciences, Inc. reported a gross profit of 79.20M and revenue of 6.96B. Therefore, the gross margin over that period was 1.1%.

BMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.

GILD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Gilead Sciences, Inc. reported an operating income of 2.59B and revenue of 6.96B, resulting in an operating margin of 37.2%.

BMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.

GILD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Gilead Sciences, Inc. reported a net income of 2.02B and revenue of 6.96B, resulting in a net margin of 29.0%.

BMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.

Frequently Asked Questions

Can I hold both GILD and BMY in my portfolio?

GILD and BMY have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, GILD or BMY?

GILD has higher volatility (7.30%) compared to BMY (6.06%). In terms of maximum drawdown, GILD dropped -70.83% vs BMY's -72.03%.

Which has better risk-adjusted returns?

GILD currently has the higher Sharpe Ratio (0.81 vs 0.74), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.